WorldPing
WorldPingArs Technica
Outrage grows as CDC reportedly poised to fund "unethical" vaccine trial
CDC allocated $1.6M for study on alleged harms of hepatitis B vaccine.
Brief by WorldPing · Original reporting by Ars Technica
Clinical trial of a prion disease drug candidate begins enrolling participants
What happened
Article URL: https://www.broadinstitute.org/news/clinical-trial-prion-disease-drug-candidate-begins-enrolling-participants Comments URL: https://news.ycombinator.com/item?id=50028027 Points: 25 # Comments: 2…
Key facts
- Article URL: https://www.broadinstitute.org/news/clinical-trial-prion-disease-drug-candidate-begins-enrolling-participants Comments URL: https://news.ycombinator.com/item?id=50028027 Points: 25 # Comments: 2…
- Reported by Hacker News and published Fri, 09 Oct 2026 23:53:08 UTC.
Why it matters
Platform, chip and AI decisions set the terms other companies have to build on, so a single announcement here tends to ripple through products, supply chains and regulation.
What to watch next
- Availability, pricing and rollout regions
- Independent testing or verification of the claims made
- Responses from regulators and competing platforms
Coverage timeline
When each newsroom published on this story, oldest first — all times UTC.
Outrage grows as CDC reportedly poised to fund "unethical" vaccine trial
Clinical trial of a prion disease drug candidate begins enrolling participants
Sources
The original report was published by Hacker News. WorldPing does not claim that reporting — this page summarises and contextualises it.
Read the full report at Hacker NewsRelated WorldPing coverage
WorldPing
WorldPingThe Guardian
Controversial vaccine trial touted by RFK Jr gets go-ahead in Guinea-Bissau
Recommended dose of hepatitis B vaccine will be withheld from thousands of newborns by Danish researchers A controversial research trial that will withhold hepatitis B vaccines from some African newborns was given approval to move forward this week.
Brief by WorldPing · Original reporting by The Guardian
WorldPingSTAT
STAT+: Biotech leader, leading lab leak theorist no longer in consideration for top infectious disease role
Steven Quay, a biopharmaceutical executive with no background in infectious diseases, is no longer being considered for director of the National Institute for Allergy and Infectious Diseases.
Brief by WorldPing · Original reporting by STAT